JPMorgan upgrades Schott Pharma stock to Overweight

Published on 10/01/2026 at 12:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached EUR 281.76 million, 3.58 percent above forecast. Schott Pharma stock costs EUR 24.60 on October 1, 2026 after EUR 24.90.

Pharma-Glasfläschchen auf Fließband in moderner Produktionsanlage — SCHOTT Pharma (DE000A3ENQ51) zeigt Glasfläschchen für Medikamente auf modernem Fließband in moderner sauberer Reinraumfertigungsanlage, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) was trading at EUR 24.60 at Lang & Schwarz on October 1, 2026, down 1.20 percent from the EUR 24.90 prior close. The latest investment case combines stronger third-quarter revenue with a new positive analyst view from JPMorgan.

Revenue beats forecast in Q3

According to Investing.com, Schott Pharma generated EUR 281.76 million of revenue in the third quarter of 2026, exceeding the EUR 272.03 million forecast by EUR 9.73 million, or 3.58 percent. The figure gives the stock a concrete operating counterweight to its daily decline.

The same Q3 2026 summary says full-year revenue growth guidance rose to 5.00-6.00 percent from 2.00-5.00 percent. Full-year margin guidance was lifted to 27.00-28.00 percent, although the third-quarter EBITDA margin fell to 26.80 percent from 32.30 percent a year earlier, keeping profitability central to the valuation debate.

JPMorgan sets EUR 27.10 target

On September 15, 2026, Finanznachrichten reported that JPMorgan initiated coverage with an Overweight rating and a EUR 27.10 price target. The bank cited Schott Pharma's position in containment and delivery systems for injectable medicines and projected annual earnings growth potential of 14.00 percent through 2029.

Against the EUR 24.60 Lang & Schwarz price, JPMorgan's target lies 10.16 percent above the reference price. That comparison matters because the target is only a market view, while the Q3 figures show the operating progress that must support the longer-term earnings case.

Stock stays near its yearly high

The EUR 24.60 price is 2.57 percent below the finance quote's EUR 25.25 52-week high as of October 1, 2026. Market capitalization stood at EUR 3.7 billion on the same date, while the stock remained within a 52-week range of EUR 12.62 to EUR 25.25.

Marketscreener lists December 9, 2026 as the next annual earnings release date. The date places the next major test of the raised growth outlook after the fiscal year ending September 30, 2026.

Price and investor reference

At Lang & Schwarz, Schott Pharma was trading at EUR 24.60 on October 1, 2026 at 12:04 p.m. CEST, down 1.20 percent versus the EUR 24.90 prior close at Lang & Schwarz. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.